American National Bank Sells 2,957 Shares of Johnson & Johnson (NYSE:JNJ)

American National Bank lowered its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 4.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,991 shares of the company’s stock after selling 2,957 shares during the quarter. Johnson & Johnson makes up about 2.7% of American National Bank’s holdings, making the stock its 8th largest holding. American National Bank’s holdings in Johnson & Johnson were worth $11,359,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $26,000. RE Dickinson Investment Advisors LLC lifted its stake in Johnson & Johnson by 163.3% in the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC boosted its holdings in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares during the last quarter. Professional Financial Advisors LLC grew its position in shares of Johnson & Johnson by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock valued at $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Joseph P. Lucia & Associates LLC purchased a new position in Johnson & Johnson during the first quarter worth approximately $38,000. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $164.97 on Wednesday. The company’s 50 day simple moving average is $168.71 and its 200-day simple moving average is $174.30. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a market capitalization of $433.74 billion, a price-to-earnings ratio of 24.01, a price-to-earnings-growth ratio of 2.97 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter in the previous year, the company earned $2.48 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.74%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson declared that its board has authorized a stock repurchase plan on Wednesday, September 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the company to repurchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research note on Wednesday, June 22nd. They issued an “outperform” rating for the company. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. SVB Leerink decreased their target price on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. UBS Group dropped their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a research note on Thursday, July 21st. Finally, Citigroup reduced their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.78.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.